CG Oncology reported its Q1 2026 financials emphasizing ongoing Phase 3 PIVOT-006 trial developments targeting intermediate-risk NMIBC, reflecting steady clinical advancement critical to regulatory positioning. The company maintains a strong liquidity profile with $33.7 million cash against minimal debt, supporting continued trial execution. Positioned exclusively in bladder cancer therapeutics, CG Oncology’s progress hinges on achieving clear pivotal data readouts and navigating regulatory pathways amid inherent clinical and financial risks.